Siti Munira Abd Jalil1,2, Jack Henry1, John F Marshall1, Angus Cameron1
1. Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London UK
2. Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, National Institutes of Health Malaysia
*Corresponding author: Siti Munira Abd Jalil.
ABSTRACT
INTRODUCTION: Breast cancer remains the most common type of diagnosed malignancy worldwide. However, treatment resistance remains a challenge in treating breast cancers. Targeting the tumour microenvironment (TME) increasingly appears to be a viable strategy as we gradually uncover the roles of non-cancerous cells within the tumour in modulating both progression of disease and responses towards treatment. Protein Kinase N2 (PKN2) is a key regulator of the YAP/TAZ-TEAD pathway, which drives resistance to cancer therapies. PKN2 controls this pathway in cancer-associated fibroblasts (CAFs), supporting their tumour-promoting functions. Targeting PKN2 may help disrupt CAF activity and reduce therapy resistance.
OBJECTIVE(S): This study aimed to explore the changes in immune profile following PKN2 modulation of the breast tumour stroma.
MATERIALS & METHODS: Tumour blocks from our novel inducible PKN2 knockout mouse, (iPKN2: PKN2fl/fl; Rosa26-CreERT2) were analysed for transcriptomic study utilising Smart-3SEQ protocol and immunohistochemistry.
RESULTS: Intriguingly, transcriptomic profiling and immunohistochemistry revealed a change in the immune landscape of the PKN2 knockout tumours towards an inflammatory and immunogenic phenotype, driven by CAF inactivation and downregulation of TGF-β signalling.
CONCLUSION: This could potentially promote better response towards immune check point inhibitors and limit CAF-mediated treatment resistance.
KEYWORDS: Triple negative breast cancer (TNBC), Resistance, Cancer-associated fibroblasts (CAFS), HIPPO, Yes-associated protein (YAP)/ Transcriptional co-activator with PDZ-binding motif (TAZ)


